Hyundai Bioscience Co., Ltd.

KOSDAQ:A048410 Stock Report

Market Cap: ₩577.0b

Hyundai Bioscience Past Earnings Performance

Past criteria checks 0/6

Hyundai Bioscience's earnings have been declining at an average annual rate of -26.8%, while the Personal Products industry saw earnings growing at 13.8% annually. Revenues have been declining at an average rate of 20.2% per year.

Key information

-26.8%

Earnings growth rate

-25.3%

EPS growth rate

Personal Products Industry Growth3.8%
Revenue growth rate-20.2%
Return on equity-23.9%
Net Margin-66.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?

Nov 12
Is Hyundai Bioscience (KOSDAQ:048410) A Risky Investment?

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Mar 14
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Feb 07
Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?

Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

Jan 03
Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher

The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Nov 29
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About

Revenue & Expenses Breakdown

How Hyundai Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A048410 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2415,818-10,4408,4353,349
30 Jun 2417,323-7,2918,2123,349
31 Mar 2411,369-11,2178,3633,550
31 Dec 239,481-14,4997,8356,401
30 Sep 2310,061-17,55912,2279,617
30 Jun 2310,481-12,22417,5649,617
31 Mar 238,671-15,77010,14518,646
31 Dec 227,852-15,80711,80216,456
30 Sep 228,659-18,1747,20513,820
30 Jun 228,739-24,1222,10713,820
31 Mar 229,631-19,7138,2094,556
31 Dec 219,241-20,0516,0634,763
30 Sep 218,696-13,1156,1894,021
30 Jun 219,193-10,8455,4574,021
31 Mar 2110,285-9,5535,0433,320
31 Dec 2012,511-8,2606,0701,968
30 Sep 2018,275-1,6915,5311,114
30 Jun 2021,868-5595,9161,114
31 Mar 2026,434-716,9891,053
31 Dec 1930,0861,5697,0701,290
30 Sep 1931,4814,1167,5091,406
30 Jun 1932,3634,0396,8681,797
31 Mar 1932,9263,8557,8711,968
31 Dec 1831,2363,1089,7751,703
30 Sep 1833,5692,20810,5811,849
30 Jun 1834,1272,10010,7711,947
31 Mar 1832,1642,04410,3541,908
31 Dec 1731,9701,21810,5702,050
30 Sep 1731,398-6,24414,8492,091
30 Jun 1731,790-8,99215,5482,127
31 Mar 1732,316-9,32916,1682,244
31 Dec 1636,101-8,07016,1802,115
30 Sep 1633,497-2,93411,2791,831
30 Jun 1632,63013110,4051,556
31 Mar 1638,6216929,6311,241
31 Dec 1540,6757119,0141,149
30 Sep 1541,0671,2428,684986
30 Jun 1540,6095017,831824
31 Mar 1533,182-6137,196633
31 Dec 1428,913-1,3237,146460
30 Sep 1427,058-4,4988,397629
30 Jun 1425,218-6,7359,600975
31 Mar 1424,750-8,50010,8571,265
31 Dec 1325,538-9,49911,6561,528

Quality Earnings: A048410 is currently unprofitable.

Growing Profit Margin: A048410 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A048410 is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare A048410's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A048410 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (82.1%).


Return on Equity

High ROE: A048410 has a negative Return on Equity (-23.87%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies